An historical account is presented of attempts to establish the serologic identity of Lister's pneumococcal capsular Groups T and V.
of at least two serotypes of pneumococcus had appeared the year before, there is no indication in the publications of Wright and his colleagues that cognizance was taken of this fact in the preparation of the pneumococcal vaccines employed in the initial field trials. Among Wright's associates in these investigations was F. Spencer Lister [6] .
Frederick Spencer Lister was born in Nottinghamshire, England, in 1875. He was educated in Cambridgeshire and, after attending St. Bartholomew's Hospital, qualified as M.R.C.S. in 1905. Thereafter, he served for a time as the doctor aboard a cable-laying ship and arrived in South Africa in 1907. Electing to remain in that country and following a brief period in private practice, he became associated with the mining industry. There he developed an interest in pneumonia which led to his association with Wright when the latter came to Johannesburg. It was an association that stimulated Lister's continuously productive investigations of the pneumococcus over the ensuing quarter century.
In his early studies with Wright, Lister was struck by the infrequency with which recently isolated strains of pneumococci were opsonized, even with serum of the patient from whom they were recovered. Reasoning that serum obtained at the time of crisis might opsonize the organism causing illness, Lister took isolates from blood or from material obtained by lung puncture and examined the immunologic responses in 20 cases of pneumonia meeting these criteria. Among the 14 cases which recovered, opsonization and agglutination by the patient's serum of the pneumococci causing infection were observed in 12, whereas among the six who died, these phenomena were noted only in two [7] . There are several explanations for the probable failure to The prophylactic pneumococcal vaccine now so extensively used on these fields may, in the light of these studies become modified; it is obvious that the efficacy of such vaccine would be enhanced if use were made of the particular strain of organism to infection by which the labourers will be exposed. It may also be found advantageous to use certain definite combinations of strains. . . .
The serum therapy of pneumonia, which has not hitherto afforded notable results, may derive additional importance when it can be used in so specific a manner as the results of these investigations lead me to hope.
Lister's report coincided closely with one describing studies conducted independently at the Rockefeller Institute, and his text bears the following postscript:
Since committing the above to paper my attention has been drawn to some recent work by A.R. Dochez and L.J. Gillespie and which has appeared in the Journal of the American Medical Association for September 6th, 1913 (pages 727-730). Although these workers have adopted different methods of investigation, yet their observations seem to have led them to conclusions somewhat similar to my own.
Over the ensuing two decades the number of pneumococcal groups identified in South Africa expanded gradually from the four defined in the initial report of 1913 to seven in 1916 [8] , 10 in 1917 [9] , 15 or 16 in 1931 [10] , and 21 in 1935 [11] , all designated by capital letters. In the same period, the serotypes of pneumococci classified originally in Dochez and Gillespie's Group IV were scrutinized in a number of laboratories in North America and in Europe, culminating in the publications of Cooper and her associates, who, by 1931, had recognized 33 capsular serotypes of pneumococci [12] . It is of historical interest to note that this immunologic classification of an encapsulated organism was accomplished without utilization of the Quellung reaction, described originally by Neufeld in 1902 [13] .
In 1938, David Ordman, an associate of Lister, published a report entitled: "Pneumococcus Types in South Africa. A Study of their Occurrence and Distribution in the Population and the Effect Thereon of Prophylactic Inoculation" [14] . In it, there is a reconciliation of the South African and American designations of pneumococcal types. Of 30 American capsular types (types 26 and 30 were considered identical with types 6 and 15), all but those numbered 31 and 32 had been recognized in South Africa. Of the 30 designated South African Groups (types), all but Groups T and V had their counterparts in Cooper's classification. It should be noted that pneumococci in South African Groups (types) D, F, G, H, J, L, and P were not available for study and that supplies of antiserum to these groups had been exhausted, so that it was no longer possible to determine their identities in other schemes of classification. The table reconciling Lister's and Cooper's nomenclatures may be found in Appendix B of Heffron's monograph [4] .
Pneumococcal Groups T and V are cited for the first time in Lister and Ordman's publications in 1935 [11] , and the incidence of infection with the former was evidently great enough to lead to its inclusion in the polyvalent whole bacterial vaccine used for the prevention of pneumonia at that period. In Ordman's study of 879 pneumococcal isolates from unvaccinated native Africans with pneumonia, strains of Group T ranked seventh in frequency, accounting for 1.4 percent of all isolates, and those of Group V ranked eighth, together with types 5 and 8, each accounting for 1.1 percent of the strains recovered. Regrettably, no data on bacteremic illness are provided. Among 170 Europeans with pneumonia, pneumococcus Group T was recovered from one, and there were two isolates of capsular Group V [14] .
Work on the delineation of additional pneumococcal types continued in the 1940s, both in Denmark and in the United States, and included studies of unclassified strains provided to laboratories in both countries by Ordman Cross-absorbtion of Eddy's type 73 shows identity with type 46 (Lund, 1950) . Either strain reacts with type 44. Type 46 is identical with Type T which was established in South Africa by Ordman (1938) . Eddy is mistaken when she declares her type 72 identical with type T (Eddy, 1944, p. 450). Type 46 (strain "T") and Eddy's strain 73 are both highly virulent for mice [17] . It is clear that there is an unreconciled disagreement between Eddy's and Lund's classification of pneumococci of South African Group (type) T in the Danish and American nomenclatures of capsular types. Interestingly, there is no mention in any of the reports cited of pneumococci of South African Group V, a serotype found with a frequency only slightly less than that of Group T.
In November 1974, in the course of the field trials of pneumococcal vaccine being conducted then in South Africa [18] , an attempt was made to locate strains of pneumococci in groups classified by Lister [19] . In the United States, there were only two isolates of type 45 and three of type 46 among 4,335 pneumococcal strains recovered from blood cultures in the past two decades [20] . Whether or not there is a genetic predisposition to infection with these two pneumococcal types in certain ethnic groups in Southern Africa and in Papua-New Guinea is unknown, although a relationship between human genotype and susceptibility to infection with certain capsulated bacteria has been suggested, but not established, by several groups of investigators [21, 22] . The structure of the capsular polysaccharides of pneumococcal types 45 [23] and 46 [24] has each been established recently, information which may be helpful in understanding ultimately their infectivity, and both polymers have been incorporated in experimental vaccines. The work begun by Lister and his associates 70 years ago in South Africa continues to bear fruit.
